Essential hypertension
Conditions
Interventions
All participants undergo percutaneous transluminal catheter radiofrequency ablation in renal artery with 5Fr ablation catheter approved for treating cardiac arrhythmia. Initial 3 cases undergo 4W x 60
Sponsors
Department of Advanced Cardiovascular Therapeutics, Osaka University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Maintaining systolic blood pressure not less than 160mmHg (or 150mmHg with diabetes mellitus) under 3 or more kinds of anti-hypertensive medication. 2) Undergoing introduction about this study and give written informed consent.
Exclusion criteria
Exclusion criteria: 1) Renal anomaly or incompetency: Narrowing, previous renal angioplasty or stenting, or bifurcation. 2) Estimated glomerular filtration ratio less than 45mL/min. 3) Myocardial infarction, angina pectoris, or cerebrovascular disorder within recent 6 months. 4) Type 1 diabetes. 5) Secondary hypertension. 6) Prominent bleeding risk or coagulating disorder. 7) Diagnosed as any non-cardiovascular disease with less than 12 months more to live. 8) Current participants for any other clinical trial, excluding under extended observation period for evaluating approved drugs or materials. 9) Pregnancy. 10) Disqualified by any cardiologist for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) No severe adverse effect after completion of protocol. 2) Lower blood pressure measures after 1, 3, 6, 12 months of operation than control with unchanged medication, or normalized pressure with reduced medication. | — |
Countries
Japan
Contacts
Public ContactYuji Okuyama
Osaka University Graduate School of Medicine Department of Advanced Cardiovascular Therapeutics
Outcome results
None listed